tropifexor   Click here for help

GtoPdb Ligand ID: 9725

Synonyms: compound 1 [PMID: 29148806] | LJN452
PDB Ligand
Compound class: Synthetic organic
Comment: Tropifexor (LJN452) is a potent non-bile acid agonist of the ligand-activated nuclear farnesoid X receptor (FXR) [1] that is being developed by Novartis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 126.16
Molecular weight 603.15
XLogP 6.82
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES OC(=O)c1cc(F)c2c(c1)sc(n2)N1C2CCC1CC(C2)OCc1c(onc1c1ccccc1OC(F)(F)F)C1CC1
Isomeric SMILES OC(=O)c1cc(F)c2c(c1)sc(n2)N1[C@@H]2CC[C@H]1C[C@H](C2)OCc1c(onc1c1ccccc1OC(F)(F)F)C1CC1
InChI InChI=1S/C29H25F4N3O5S/c30-21-9-15(27(37)38)10-23-25(21)34-28(42-23)36-16-7-8-17(36)12-18(11-16)39-13-20-24(35-41-26(20)14-5-6-14)19-3-1-2-4-22(19)40-29(31,32)33/h1-4,9-10,14,16-18H,5-8,11-13H2,(H,37,38)/t16-,17+,18+
No information available.
Summary of Clinical Use Click here for help has three Phase 2 LJN452 trials registered, that are evaluating the compound in patients with cholestatic liver diseases and nonalcoholic steatohepatitis (NASH).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The molecular mechanism that is effective in NASH is thought to be FXR activation leading to suppressed lipogenesis and elevated triglyceride oxidation and clearance, which in turn leads to reduced liver steatosis, inflammation and fibrosis.